Press Room

Bioprocessing Summit Europe

Start
Tuesday, March 20, 2018 - 00:00
End
Thursday, March 22, 2018 - 00:00
Location: Lisbon, Portugal
Booth Number: 9

Bioprocessing Summit Europe brings together leading bioprocessing scientists to share day-to-day challenges and practical solutions for today's bioprocessing needs. 

Hovione is present at the Bioprocessing Summit Europe with a Booth (# 9) and with a presentation by Márcio Temtem.

 

HOVIONE PRESENTATION

Spray drying - a viable alternative to biopharmaceuticals?

Date/Time: Thursday, March 22nd, 9:30

Room: White Plains 5

Presentation abstract:

Spray drying is presently one of the most exciting technologies in the pharmaceutical industry with several commercial products approved each year.

The relevance of the technology is in part explained by the fact it is a scalable drying process suitable to convert liquid streams into dry powders with a broad range of properties. Such flexibility led to its application in a variety of pharmaceutical formulations: from very fine powders for inhalation to large particles for direct compression, or from solid dispersions for enhanced bioavailability to microcapsules for controlled release. The process considers the fine spraying of a liquid into a hot gas, evaporating, drying and collecting the solid particles from the gas stream. The process is very fast and product-gas contact very short. Due to the intensive evaporative during the drying, temperature in the droplet remains relatively low, making the process suitable for the processing of thermos labile materials like biopharmaceuticals (e.g. proteins, peptides or antibodies).  In this talk the authors will present examples of such processes and the advantages of spray drying over conventional technologies.

 

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us.

 

Our colleague, Marcel Hogerheide will be pleased to meet you.

Marcel Hogerheide  | Hovione

Marcel Hogerheide

Head of Account Management & Business Development
 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026